Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics (NASDAQ: SYRE) announced management will participate in three investor conferences in March 2026: TD Cowen Health Care (Boston) on March 3, Leerink Global Healthcare (Miami) on March 9, and Jefferies Biotech on the Beach (Miami) on March 10.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spyre Therapeutics (NASDAQ: SYRE) announced management will participate in three investor conferences in March 2026: TD Cowen Health Care (Boston) on March 3, Leerink Global Healthcare (Miami) on March 9, and Jefferies Biotech on the Beach (Miami) on March 10.
Management will host one-on-one investor meetings and provide live audio webcasts and replays via the company investor events website.
Details
News Market Reaction – SYRE
On Feb 25, the first trading day after this news, SYRE closed 0.99% above the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
Key Figures
- TD Cowen conference date
- March 3, 2026
- TD Cowen 46th Annual Health Care Conference presentation date
- TD Cowen presentation time
- 3:10 pm ET
- Spyre presentation and fireside time at TD Cowen conference
- Leerink conference date
- March 9, 2026
- Leerink Global Healthcare Conference fireside chat date
- Leerink fireside time
- 8:40 am ET
- Spyre fireside time at Leerink Global Healthcare Conference
- Jefferies summit date
- March 10, 2026
- Jefferies Biotech on the Beach Summit participation date
- Number of March events
- 3 conferences
- Total investor conferences listed in March 2026
- TD Cowen edition
- 46th annual
- Edition of TD Cowen Health Care Conference
- Price move pre-news
- 2.24%
- SYRE 24h price change ahead of this conference announcement
Historical Context
-
Reported 2025 results, strong cash runway and multiple 2026 proof-of-concept readouts.
-
ECCO data on SPY003, SKYLINE trial and superior dual-targeting preclinical results.
-
Granted 30,200 inducement stock options to new employees under equity plan.
-
Equity inducement grant for newly appointed Chief Commercial Officer under 2018 plan.
-
Outlined six 2026 POC readouts and cash balance expected to fund into H2 2028.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:
Event: TD Cowen 46th Annual Health Care Conference - Boston
Date: Tuesday, March 3, 2026
Presentation and Fireside Time: 3:10 pm ET
Event: Leerink Global Healthcare Conference – Miami
Date: Monday, March 9, 2026
Fireside Time: 8:40 am ET
Event: Jefferies Biotech on the Beach Summit – Miami
Date: Tuesday, March 10, 2026
Members of the Spyre management team will host one-on-one investor meetings during the conferences.
Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, visit Spyre's website at www.spyre.com.
For Investors:
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
Eric.mcintyre@spyre.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.